Announcements Trials
Browse Landscape

Phase

Phase 2 166Phase 1 70Phase 1/2 35Phase 3 33Phase NA 18Phase EARLY_PHASE1 6Phase 2/3 4Phase 4 3

Status

Unknown 3Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Recurrence 7Multiple Myeloma 6Neoplasms 5Burkitt Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Waldenstrom Macroglobulinemia 2Solid Tumor 2Small Cell Lung Carcinoma 2Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Melanoma 2Medulloblastoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Large Granular Lymphocytic 2Intraocular Lymphoma 2

Interventions

Cyclophosphamide 6Dexamethasone 5fludarabine 4Bortezomib 468Ga-pentixafor 4Melphalan 3Lenalidomide 3Granulocyte Colony-Stimulating Factor 3Positron Emission Tomography Computed Tomography 2Fluorodeoxyglucose F18 2Filgrastim 2tocilizumab 1ruxolitinib 1pomalidomide 1methyl prednisolonate 1ioversol 1iberdomide 1fludarabine phosphate 1eltrombopag 1elotuzumab 1daratumumab 1carfilzomib 1blinatumomab 1Thalidomide 1Tacrolimus 1Simvastatin 1Prochlorperazine 1Pemetrexed 1Ondansetron 1Mycophenolic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Multiple Myeloma × Cyclophosphamide × Clear all
NCT06142396 2026-03-12

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Augusta University

Phase EARLY_PHASE1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT05008536 2021-11-23

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Xinqiao Hospital of Chongqing

Phase EARLY_PHASE1 Unknown
27 enrolled
Plasma cell

Multiple Myeloma

NCT03943472 2021-08-31

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Hrain Biotechnology Co., Ltd.

Phase EARLY_PHASE1 Unknown
10 enrolled
Plasma cell

Multiple Myeloma

NCT04626752 2020-11-13

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Hebei Senlang Biotechnology Inc., Ltd.

Phase EARLY_PHASE1 Unknown
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02447055 2016-07-12

Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma

Washington University School of Medicine

Phase EARLY_PHASE1 Withdrawn
Plasma cell

Multiple Myeloma

NCT01537861 2015-01-26

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Washington University School of Medicine

Phase EARLY_PHASE1 Terminated
7 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡